Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is well-positioned with a strong product pipeline, significant market potential, and a promising anti-VEGF drug in TH103. However, it will need to manage competition and navigate potential financial risks to fully capitalize on its potential and achieve success in the market. Continued success in clinical trials and strategic partnerships could further drive the company's value and stock price in the long term.

Bears say

Kalaris Therapeutics is highly dependent on the success of TH103 and ADVM-022, with potential competition from existing treatments in the $15 billion market for wet AMD. The company's Outperform rating and $17 price target reflect positive clinical trial results for TH103 and the potential for expansion into other retinal diseases, but the risks and uncertainties in the development and approval process must also be considered. Additionally, the company's gene therapy, ADVM-022, is not scheduled for Phase 3 testing until 2027, which may make it difficult to compete with established treatments in the market.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.